858 results on '"Ishioka, Chikashi"'
Search Results
102. [Corrigendum] lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma
103. Somatic alteration and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma
104. Functional Complementation Assay for 47 MUTYH Variants in a MutY-Disrupted Escherichia Coli Strain
105. Relationship between smoking and multiple colorectal cancers in patients with Japanese Lynch syndrome: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum
106. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors
107. Comparison of clinical features between suspected familial colorectal cancer type X and Lynch syndrome in Japanese patients with colorectal cancer: a cross-sectional study conducted by the Japanese Society for Cancer of the Colon and Rectum
108. Prospective Comparison of Surgery Alone and Chemoradiotherapy With Selective Surgery in Resectable Squamous Cell Carcinoma of the Esophagus
109. Acute exacerbation of paraneoplastic neurological syndrome after massive tumor lysis of neuroendocrine carcinoma by chemoradiotherapy
110. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer
111. Aberrant splicing caused by a MLH1 splice donor site mutation found in a young Japanese patient with Lynch syndrome
112. IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas
113. Tumor suppressor miR‐193a‐3p enhances efficacy of BRAF/MEK inhibitors in BRAF ‐mutated colorectal cancer
114. MO28-1 Change in status of medical oncology in Japan over a seven-year period
115. Abstract 2361: The functional roles of miRNA-193a-3p in colorectal cancer
116. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring HER2 amplification (JUPITER trial).
117. Factors Related to Specialized Palliative Care Use and Aggressive Care at End of Life in Japanese Patients With Advanced Solid Cancers: A Cohort Study
118. Three cases of kindred with familial breast cancer in which carrier detection by BRCA gene testing was performed on family members
119. Multidisciplinary approach to a case of Lynch syndrome with colorectal, ovarian, and metastatic liver carcinomas
120. Quality of guideline development assessed by the Evaluation Committee of the Japan Society of Clinical Oncology
121. Determination of splice-site mutations in Lynch syndrome (hereditary non-polyposis colorectal cancer) patients using functional splicing assay
122. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
123. Comparison of cisplatin and 5-fluorouracil chemotherapy protocols combined with concurrent radiotherapy for esophageal cancer
124. lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma
125. Patients’ understanding of communication about palliative care and health condition in Japanese patients with unresectable or recurrent cancer: a cross-sectional survey
126. Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin‐based or irinotecan‐based therapy for colorectal cancer
127. TP53signature predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: Observational and confirmational study using prospective study cohorts
128. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation
129. O-[18F]fluoromethyl-L-tyrosine is a potential tracer for monitoring tumour response to chemotherapy using PET: an initial comparative in vivo study with deoxyglucose and thymidine
130. [alpha]-Catenin is essential in intestinal adenoma formation
131. The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library
132. LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK‐A11
133. Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203)
134. A novel germline mutation of the LKB1 gene in a patient with Peutz-Jeghers syndrome with early-onset gastric cancer
135. Expression of an amino-terminal BRCA1 deletion mutant causes a dominant growth inhibition in MCF10A cells
136. Identification and evaluation of 55 genetic variations in the BRCA1 and the BRCA2 genes of patients from 50 Japanese breast cancer families
137. Harmonization of Cardiovascular and Oncology and the Blossoming of Cardio-Oncology in Japan
138. Analysis of BRCA1 Variants in Double-Strand Break Repair by Homologous Recombination and Single-Strand Annealing
139. The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
140. Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors
141. BRCA1 mutation testing for Japanese patients with ovarian cancer in breast cancer screening
142. Mutational analysis of p51A/TAp63γ, a p53 homolog, in non-small cell lung cancer and breast cancer
143. BRCA1 contributes to transcription-coupled repair of DNA damage through polyubiquitination and degradation of Cockayne syndrome B protein
144. Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis
145. Contribution of autophagic cell death to p53-dependent cell death in human glioblastoma cell line SF126
146. Abstract 953: Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic tumor cells induce anti-tumor immunity
147. Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients
148. Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC).
149. Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei
150. Computational and cellular studies reveal structural destabilization and degradation of MLH1 variants in Lynch syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.